$CIPLA Cipla continues to strengthen its position across respiratory, chronic therapies, generics, and specialty pharmaceuticals, supported by a diversified product portfolio and strong domestic as well as international presence. Growth in branded formulations, respiratory products, and differentiated launches, along with expanding opportunities in complex generics, supports long-term business prospects. The company also focuses on operational efficiency, innovation, and regulatory compliance to enhance competitiveness. However, pricing pressure in the US generics market, regulatory inspections, currency fluctuations, and raw material costs remain key factors influencing revenue growth and overall financial performance. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes ***** must verify information before investing and consider their financial position & risk profile. please read full disclosure disclaimer in given link visit website www dot investmentcure dot com *****

#FundamentalViews

627 likes·72 comments